0:49
Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab
Julia von Tresckow
1:08
Can concepts from CLL be applied to other liquid and solid tumors?
Paolo Ghia
1:00
Why is personalized medicine important for CLL?
Petra Langerbeins
1:08
The impact of genetic testing on treatment selection in CLL
Anna Schuh
1:38
What are the economics of treating CLL?
John Gribben
1:14
Prognostic markers for CLL – how do they help determine who gets which treatment?
Petra Langerbeins
2:08
How does an understanding of the microenvironment aid research in CLL?
Paolo Ghia
1:02
How to explain the ‘watch-and-wait’ period to a CLL patient?
Petra Langerbeins
1:15
The role of transplant in CLL and Richter’s transformation today
Stephan Stilgenbauer
1:58
Whole genome sequencing in CLL: challenges and benefits
Anna Schuh
2:32
The importance of collaboration across fields and institutions
Dan Landau
2:23
Key considerations for mutation detection in CLL
Anna Schuh
2:10
Overview of CLL12 trial of ibrutinib aiming to delay chemoimmunotherapy
Petra Langerbeins
2:02
Current research at Weill Cornell and the New York Genome Center
Dan Landau
1:07
Where are we with precision medicine for CLL?
John Gribben
2:09
Overview of the CLL13 trial: replacing chemotherapy with venetoclax-containing regimens
Julia von Tresckow
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals